查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933381

全球胃肠道治疗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Gastrointestinal Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 225 Pages | 商品交期: 请询问到货日

价格

胃肠道（GI）治疗市场成长因子

受胃肠道疾病盛行率和认知度不断提高以及药物研发持续创新的推动，全球胃肠道（GI）治疗市场正经历稳定成长。胃肠道治疗药物包括用于治疗胃食道逆流（GERD）、发炎性肠道疾病（IBD）、肠躁症（IBS）、胃肠道癌症和其他功能性消化系统疾病的药物。根据 Fortune Business Insights 预测，到 2025 年，全球胃肠道治疗市场规模将达到 806 亿美元，凸显了全球对有效消化系统健康治疗的巨大需求。

市场规模及预测

预计到2026年，全球胃肠道疾病治疗市场规模将增长至891.1亿美元，主要驱动因素包括诊断率的提高、抑酸治疗需求的强劲增长以及生物製剂在慢性胃肠道疾病治疗中的应用日益广泛。长期来看，预计该市场在预测期内将以5.09%的复合年增长率成长，到2034年达到1,409.8亿美元。

截至2025年，北美地区以42.32%的市占率引领全球胃肠道疾病治疗市场。这主要得益于该地区较高的疾病盛行率、完善的医疗保健基础设施以及先进疗法的早期应用。

市场驱动因素

推动市场成长的关键因素之一是全球胃肠道疾病盛行率的不断上升。 生活方式的改变，例如不健康的饮食、缺乏运动、饮酒量增加和压力，显着加剧了胃肠道疾病的负担。不断扩大的患者群体推动了对有效治疗方案和先进诊断技术的需求。

据克罗恩病和结肠炎基金会统计，截至2023年6月，美国将有160万至310万人患有发炎性肠道疾病，凸显了长期疾病管理和促进药物创新的必要性。

市场限制因子

儘管市场稳定成长，但由于先进疗法（尤其是生物製剂和标靶疗法）的高昂成本，市场仍面临许多限制因素。这些疗法需要大量的研发投入，而且价格昂贵，难以取得，尤其是在中低收入国家。 有限的保险覆盖范围进一步加重了病患的经济负担。

例如，据报道，在美国，5 mg/kg剂量的英夫利西单抗的总费用约为2,634美元，这限制了先进疗法的成本效益，并减缓了其广泛应用。

市场机会

对生物製剂和标靶疗法的日益关注带来了巨大的成长机会。与旨在缓解症状的传统药物不同，生物製剂可针对特定的发炎通路，从而提高疗效并实现长期缓解，尤其是在发炎性肠道疾病（IBD）患者中。此外，生物相似药和下一代口服疗法的开发有望提高药物的可负担性和市场渗透率。

2024年6月，美国FDA批准了SKYRIZI（risankizumab-rzaa）用于治疗中度至重度活动性溃疡性结肠炎，这标誌着生物製剂的应用势头日益强劲。

市场趋势

影响市场的一个显着趋势是，人们越来越重视早期筛检和预防性诊断。医疗保健系统正致力于透过分子诊断、生物标记检测和基于人工智慧的内视镜成像技术，早期发现胃肠道癌症和慢性疾病。这些进步正在改善患者的治疗效果，同时也推动了对综合治疗和诊断解决方案的需求。

市场挑战

限制市场扩张的主要挑战是常用胃肠道药物相关的不良反应风险和长期安全性问题。例如，长期使用质子帮浦抑制剂 (PPI) 与肾臟疾病、营养不良、骨折和感染有关。 监管警告和谨慎的处方实践正在抑制某些传统药物细分市场的成长。

细分市场分析

依产品类型划分，小分子药物和传统药物将主导市场，在2026年占71.36%的市场占有率，这主要得益于其价格实惠和广泛的可及性。

依治疗方法划分，抑酸疗法将在2026年占市场主导地位，市占率为23.84%，主要得益于胃食道逆流（GERD）的高发生率和非处方药（OTC）的强劲需求。

依给药途径划分，口服给药途径将主导市场，在2026年占70.41%的市场占有率，这主要得益于其便利性和较高的患者依从性。

依应用领域划分，发炎性肠道疾病（IBD）将占最大市场占有率，这主要得益于其高昂的治疗费用和患者意识的提高。

依分销管道划分，零售药局和药局将引领市场，到 2025 年将占 50.9% 的市场占有率。

区域展望

北美将引领市场，2025 年市场规模将达到 358 亿美元，2026 年将达到 376.9 亿美元，主要得益于积极的研发活动和较高的疾病负担。

预计到 2025 年，欧洲市场规模将达到 218.1 亿美元，而亚太地区市场规模预计将达到 209.5 亿美元，这主要得益于中国和印度医疗基础设施的改善。

拉丁美洲和中东及非洲的成长速度将放缓，预计到 2025 年，市场规模将分别达到 34.4 亿美元和 12.6 亿美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 概述：胃肠道治疗领域的技术进步
  • 主要国家的监管状况
  • 主要产业趋势：併购（併购）、业务合作等
  • 新产品发布：依主要公司划分

第五章 全球胃肠道治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品类型划分
    • 小分子药物/传统药物
    • 生物製剂/生物相似药
  • 市场分析、洞察与预测：依疗法划分
    • 抑酸疗法
      • 质子帮浦抑制剂 (PPI)
      • 其他
    • 标靶疗法
      • 抗体
      • JAK抑制剂
      • 其他
    • 抗发炎药物和免疫调节剂
    • 抗生素
    • 止吐药
    • 促动力药和促分泌药
    • 其他
  • 市场分析、洞察与预测：依给药途径
    • 口服
    • 肠外给药
    • 其他
  • 市场分析、洞察与预测：依年龄组
    • 儿科
    • 成人
  • 市场分析、洞察与预测：依应用
    • 胃食道逆流症 (GERD)
    • 功能性胃肠疾病 (FGIDs)
    • 肠躁症 (IBS)
    • 发炎性肠道疾病 (IBD)
    • 胃肠道疾病癌症
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药局和药局
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美胃肠道治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲胃肠道治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区胃肠道治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲胃肠道治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲胃肠道治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2026）
  • 公司简介
  • Johnson &Johnson
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Pfizer Inc.
  • Abbott
  • UCB S.A.
  • Bausch Health Companies Inc.
  • CELLTRION INC.
Product Code: FBI114337

Growth Factors of gastrointestinal (GI) therapeutics Market

The global gastrointestinal (GI) therapeutics market is witnessing consistent growth, driven by the rising prevalence of digestive disorders, increasing awareness, and continuous innovation in drug development. Gastrointestinal therapeutics include medications for conditions such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), GI cancers, and other functional GI disorders. According to Fortune Business Insights, the global gastrointestinal therapeutics market was valued at USD 80.60 billion in 2025, highlighting the significant demand for effective digestive health treatments worldwide.

Market Size and Forecast

In 2026, the global market is projected to grow to USD 89.11 billion, supported by increasing diagnosis rates, strong demand for acid suppression therapies, and expanding use of biologics for chronic GI conditions. Over the long term, the market is expected to reach USD 140.98 billion by 2034, registering a CAGR of 5.09% during the forecast period.

North America dominated the global gastrointestinal therapeutics market in 2025, accounting for a 42.32% market share, owing to high disease prevalence, strong healthcare infrastructure, and early adoption of advanced therapies.

Market Drivers

One of the key drivers fueling market growth is the increasing prevalence of gastrointestinal diseases globally. Lifestyle changes such as unhealthy diets, sedentary behavior, rising alcohol consumption, and stress have significantly contributed to the growing burden of GI disorders. This expanding patient population has increased demand for effective therapeutic solutions and advanced diagnostic procedures.

According to the Crohn's & Colitis Foundation, between 1.6 and 3.1 million people in the U.S. were living with inflammatory bowel disease as of June 2023, underscoring the need for long-term disease management and driving pharmaceutical innovation.

Market Restraints

Despite steady growth, the market faces restraints due to the high cost of advanced therapies, particularly biologics and targeted treatments. These therapies require extensive R&D investment, making them expensive and less accessible, especially in low- and middle-income countries. Limited insurance coverage further increases the financial burden on patients.

For example, the bundled cost of a 5 mg/kg dose of infliximab was reported at approximately USD 2,634 in the U.S., limiting affordability and slowing adoption of advanced therapies.

Market Opportunities

The rising focus on biologics and targeted therapies presents significant growth opportunities. Unlike conventional drugs that offer symptomatic relief, biologics target specific inflammatory pathways, providing improved efficacy and long-term remission, particularly in IBD patients. Additionally, the development of biosimilars and next-generation oral therapies is expected to improve affordability and market penetration.

In June 2024, the U.S. FDA approved SKYRIZI (risankizumab-rzaa) for moderately to severely active ulcerative colitis, reflecting the growing momentum in biologic drug adoption.

Market Trends

A prominent trend shaping the market is the increased emphasis on early screening and preventive diagnostics. Healthcare systems are focusing on early detection of GI cancers and chronic conditions through molecular diagnostics, biomarker testing, and AI-enabled endoscopic imaging. These advancements improve patient outcomes while supporting demand for integrated therapeutic and diagnostic solutions.

Market Challenges

A major challenge limiting market expansion is the risk of adverse drug reactions and long-term safety concerns associated with commonly used GI medications. For instance, prolonged use of proton pump inhibitors (PPIs) has been linked to kidney disease, nutrient deficiencies, bone fractures, and infections. Regulatory warnings and cautious prescribing practices have moderated growth in certain traditional drug segments.

Segmentation Analysis

By product type, small molecules and conventional drugs dominated the market, holding a 71.36% share in 2026, driven by affordability and widespread availability.

By therapy type, acid suppression therapies led the market with a 23.84% share in 2026, supported by high GERD prevalence and strong OTC demand.

By route of administration, the oral segment dominated with a 70.41% share in 2026, due to convenience and high patient adherence.

By application, inflammatory bowel disease (IBD) accounted for the largest share, driven by high treatment costs and rising patient awareness.

By distribution channel, retail pharmacies and drug stores led the market, holding 50.9% share in 2025.

Regional Outlook

North America led the market with USD 35.80 billion in 2025 and USD 37.69 billion in 2026, driven by strong R&D activity and high disease burden.

Europe reached USD 21.81 billion in 2025, while Asia Pacific recorded USD 20.95 billion in 2025, supported by improving healthcare infrastructure in China and India.

Latin America and Middle East & Africa showed moderate growth, with valuations of USD 3.44 billion and USD 1.26 billion respectively in 2025.

Competitive Landscape

The global market is semi-consolidated, with key players such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Pfizer Inc., and Bristol Myers Squibb leading due to diversified portfolios, strong pipelines, and global distribution networks. Continuous product approvals and biologic innovation support their dominance.

Conclusion

The global gastrointestinal therapeutics market is set to grow steadily from USD 80.60 billion in 2025 to USD 140.98 billion by 2034, driven by rising prevalence of GI disorders, expanding use of biologics, and growing focus on early diagnosis and preventive care. Although high treatment costs and safety concerns pose challenges, continuous R&D investments, targeted therapies, and biosimilar development are expected to enhance treatment accessibility and long-term disease management. Overall, the market will continue to evolve as a critical component of global healthcare, addressing the increasing burden of digestive diseases worldwide.

Segmentation By Product Type

  • Small Molecules/Conventional Drugs
  • Biologics & Biosimilars

By Therapy Type

Acid Suppression Therapies

  • Proton Pump Inhibitor (PPI)
  • Others
  • Targeted Therapies
  • Antibodies
  • JAK Inhibitors
  • Others
  • Anti-Inflammatory & Immunomodulators
  • Antibiotics
  • Antiemetics
  • Motility Agents & Secretagogues
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Age Group

  • Pediatrics
  • Adults

By Application

  • Gastroesophageal Reflux Disease (GERD)
  • Functional Gastrointestinal Disorders (FGIDs)
  • Inflammatory Bowel Disease (IBD)
  • Irritable Bowel Syndrome (IBS)
  • GI Cancers
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

North America (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country)

  • U.S.
  • Canada

Europe (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe

Asia Pacific (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific

Latin America (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Technological Advancements in Gastrointestinal Therapeutics
  • 4.2. Regulatory Scenario, By Key Countries/Regions
  • 4.3. Key Industry Developments (Mergers, Acquisitions, and Collaborations etc.)
  • 4.4. New Product Launches, By Key Players

5. Global Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 5.1.1. Small Molecules/Conventional Drugs
    • 5.1.2. Biologics & Biosimilars
  • 5.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 5.2.1. Acid Suppression Therapies
      • 5.2.1.1. Proton Pump Inhibitor (PPI)
      • 5.2.1.2. Others
    • 5.2.2. Targeted Therapies
      • 5.2.2.1. Antibodies
      • 5.2.2.2. JAK Inhibitors
      • 5.2.2.3. Others
    • 5.2.3. Anti-Inflammatory & Immunomodulators
    • 5.2.4. Antibiotics
    • 5.2.5. Antiemetics
    • 5.2.6. Motility Agents & Secretagogues
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatrics
    • 5.4.2. Adults
  • 5.5. Market Analysis, Insights and Forecast - By Application
    • 5.5.1. Gastroesophageal Reflux Disease (GERD)
    • 5.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 5.5.3. Irritable Bowel Syndrome (IBS)
    • 5.5.4. Inflammatory Bowel Disease (IBD)
    • 5.5.5. GI Cancers
    • 5.5.6. Others
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Retail Pharmacies & Drug Stores
    • 5.6.3. Online Pharmacies
  • 5.7. Market Analysis, Insights and Forecast - By Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 6.1.1. Small Molecules/Conventional Drugs
    • 6.1.2. Biologics & Biosimilars
  • 6.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 6.2.1. Acid Suppression Therapies
      • 6.2.1.1. Proton Pump Inhibitor (PPI)
      • 6.2.1.2. Others
    • 6.2.2. Targeted Therapies
      • 6.2.2.1. Antibodies
      • 6.2.2.2. JAK Inhibitors
      • 6.2.2.3. Others
    • 6.2.3. Anti-Inflammatory & Immunomodulators
    • 6.2.4. Antibiotics
    • 6.2.5. Antiemetics
    • 6.2.6. Motility Agents & Secretagogues
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatrics
    • 6.4.2. Adults
  • 6.5. Market Analysis, Insights and Forecast - By Application
    • 6.5.1. Gastroesophageal Reflux Disease (GERD)
    • 6.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 6.5.3. Irritable Bowel Syndrome (IBS)
    • 6.5.4. Inflammatory Bowel Disease (IBD)
    • 6.5.5. GI Cancers
    • 6.5.6. Others
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies & Drug Stores
    • 6.6.3. Online Pharmacies
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 7.1.1. Small Molecules/Conventional Drugs
    • 7.1.2. Biologics & Biosimilars
  • 7.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 7.2.1. Acid Suppression Therapies
      • 7.2.1.1. Proton Pump Inhibitor (PPI)
      • 7.2.1.2. Others
    • 7.2.2. Targeted Therapies
      • 7.2.2.1. Antibodies
      • 7.2.2.2. JAK Inhibitors
      • 7.2.2.3. Others
    • 7.2.3. Anti-Inflammatory & Immunomodulators
    • 7.2.4. Antibiotics
    • 7.2.5. Antiemetics
    • 7.2.6. Motility Agents & Secretagogues
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatrics
    • 7.4.2. Adults
  • 7.5. Market Analysis, Insights and Forecast - By Application
    • 7.5.1. Gastroesophageal Reflux Disease (GERD)
    • 7.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 7.5.3. Irritable Bowel Syndrome (IBS)
    • 7.5.4. Inflammatory Bowel Disease (IBD)
    • 7.5.5. GI Cancers
    • 7.5.6. Others
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Retail Pharmacies & Drug Stores
    • 7.6.3. Online Pharmacies
  • 7.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Spain
    • 7.7.5. Italy
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 8.1.1. Small Molecules/Conventional Drugs
    • 8.1.2. Biologics & Biosimilars
  • 8.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 8.2.1. Acid Suppression Therapies
      • 8.2.1.1. Proton Pump Inhibitor (PPI)
      • 8.2.1.2. Others
    • 8.2.2. Targeted Therapies
      • 8.2.2.1. Antibodies
      • 8.2.2.2. JAK Inhibitors
      • 8.2.2.3. Others
    • 8.2.3. Anti-Inflammatory & Immunomodulators
    • 8.2.4. Antibiotics
    • 8.2.5. Antiemetics
    • 8.2.6. Motility Agents & Secretagogues
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatrics
    • 8.4.2. Adults
  • 8.5. Market Analysis, Insights and Forecast - By Application
    • 8.5.1. Gastroesophageal Reflux Disease (GERD)
    • 8.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 8.5.3. Irritable Bowel Syndrome (IBS)
    • 8.5.4. Inflammatory Bowel Disease (IBD)
    • 8.5.5. GI Cancers
    • 8.5.6. Others
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Retail Pharmacies & Drug Stores
    • 8.6.3. Online Pharmacies
  • 8.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.7.1. Japan
    • 8.7.2. China
    • 8.7.3. India
    • 8.7.4. Australia
    • 8.7.5. Southeast Asia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 9.1.1. Small Molecules/Conventional Drugs
    • 9.1.2. Biologics & Biosimilars
  • 9.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 9.2.1. Acid Suppression Therapies
      • 9.2.1.1. Proton Pump Inhibitor (PPI)
      • 9.2.1.2. Others
    • 9.2.2. Targeted Therapies
      • 9.2.2.1. Antibodies
      • 9.2.2.2. JAK Inhibitors
      • 9.2.2.3. Others
    • 9.2.3. Anti-Inflammatory & Immunomodulators
    • 9.2.4. Antibiotics
    • 9.2.5. Antiemetics
    • 9.2.6. Motility Agents & Secretagogues
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatrics
    • 9.4.2. Adults
  • 9.5. Market Analysis, Insights and Forecast - By Application
    • 9.5.1. Gastroesophageal Reflux Disease (GERD)
    • 9.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 9.5.3. Irritable Bowel Syndrome (IBS)
    • 9.5.4. Inflammatory Bowel Disease (IBD)
    • 9.5.5. GI Cancers
    • 9.5.6. Others
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Retail Pharmacies & Drug Stores
    • 9.6.3. Online Pharmacies
  • 9.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 10.1.1. Small Molecules/Conventional Drugs
    • 10.1.2. Biologics & Biosimilars
  • 10.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 10.2.1. Acid Suppression Therapies
      • 10.2.1.1. Proton Pump Inhibitor (PPI)
      • 10.2.1.2. Others
    • 10.2.2. Targeted Therapies
      • 10.2.2.1. Antibodies
      • 10.2.2.2. JAK Inhibitors
      • 10.2.2.3. Others
    • 10.2.3. Anti-Inflammatory & Immunomodulators
    • 10.2.4. Antibiotics
    • 10.2.5. Antiemetics
    • 10.2.6. Motility Agents & Secretagogues
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatrics
    • 10.4.2. Adults
  • 10.5. Market Analysis, Insights and Forecast - By Application
    • 10.5.1. Gastroesophageal Reflux Disease (GERD)
    • 10.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 10.5.3. Irritable Bowel Syndrome (IBS)
    • 10.5.4. Inflammatory Bowel Disease (IBD)
    • 10.5.5. GI Cancers
    • 10.5.6. Others
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies & Drug Stores
    • 10.6.3. Online Pharmacies
  • 10.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Johnson & Johnson
    • 11.2.2. AbbVie Inc.
    • 11.2.3. Takeda Pharmaceutical Company Limited
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. Bayer AG
    • 11.2.6. Pfizer Inc.
    • 11.2.7. Abbott
    • 11.2.8. UCB S.A.
    • 11.2.9. Bausch Health Companies Inc.
    • 11.2.10. CELLTRION INC.

List of Tables

  • Table 1: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 2: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 3: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 4: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 5: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 6: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 7: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 8: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 9: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Region, 2021-2034
  • Table 10: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 11: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 12: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 13: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 14: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 15: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 16: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 17: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 18: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 19: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 20: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 21: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 22: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 23: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 24: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 25: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 26: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 27: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 28: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 29: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 30: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 31: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 32: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 33: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 34: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 35: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 36: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 37: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 38: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 39: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 40: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 41: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 42: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 43: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 44: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 45: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 47: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 48: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 49: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 50: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 51: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 52: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 53: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 54: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Gastrointestinal Therapeutics Market Revenue Breakdown (USD Billion, %) By Region, 2026 & 2034
  • Figure 2: Global Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026 & 2034
  • Figure 3: Global Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026 & 2034
  • Figure 4: Global Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026 & 2034
  • Figure 5: Global Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026 & 2034
  • Figure 6: Global Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026 & 2034
  • Figure 7: Global Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 8: Global Gastrointestinal Therapeutics Market Value (USD Billion), By Region, 2026 & 2034
  • Figure 9: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 10: North America Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 11: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 12: North America Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 13: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 14: North America Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 15: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 16: North America Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 17: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 18: North America Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 19: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 20: North America Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 21: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Country, 2026 & 2034
  • Figure 22: North America Gastrointestinal Therapeutics Market Value Share (%), By Country, 2026
  • Figure 23: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 24: Europe Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 25: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 26: Europe Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 27: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 28: Europe Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 29: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 30: Europe Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 31: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 32: Europe Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 33: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 34: Europe Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 35: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 36: Europe Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 37: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 38: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 39: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 40: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 41: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 42: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 43: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 44: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 45: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 46: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 47: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 48: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 49: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 50: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 51: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 52: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 53: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 54: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 55: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 56: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 57: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 58: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 59: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 60: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 61: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 62: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 63: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 64: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 65: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 66: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 67: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 68: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 69: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 70: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 71: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 72: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 73: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 74: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 75: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 76: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 77: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 78: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 79: Global Gastrointestinal Therapeutics Market Share (%), By Company, 2026